Makes you wonder if our partners AstraZeneca should look at adding our DEP technology to their COVID-19 nasal spray vaccine - would our DEP technology increase antibody responses / vaccine absorption in patients I wonder ?
https://thehill.com/policy/healthca...fails-to-offer-desired-protection-in-testing/
Nasal COVID spray fails to offer desired protection in testing
A recent clinical trial has found less-than-promising results for a nasally administered version of AstraZeneca’s COVID-19 vaccine, with immune responses only observed in “a minority of participants.”
University of Oxford researchers found in their Phase 1 clinical trial that not only were antibody responses only seen in a minority of participants, but these responses were also weaker in comparison to intramuscular vaccinations. The nasal formula that was administered was the same one used for intramuscular injections.
Ann: VIRALEZE relaunched by LloydsPharmacy in the UK, page-240
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.5¢ |
Change
-0.003(3.06%) |
Mkt cap ! $39.17M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.5¢ | $12.55K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 586785 | 9.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 56840 | 1 |
View Market Depth
| Last trade - 16.10pm 23/07/2024 (20 minute delay) ? |
| SPL (ASX) Chart |